B-cell depletion for ME/CFS after infection
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This trial tests whether a drug that targets B cells (a type of immune cell) can help people with ME/CFS and PAIS who have previously improved with a blood-filtering treatment called immunoadsorption. The goal is to see if this treatment can reduce symptoms and improve function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have been diagnosed with ME/CFS (chronic fatigue syndrome) and post-acute infection syndrome (PAIS) from COVID-19 or another infection.
- You have had a specific autoantibody (ß2 adrenergic receptor antibody) detected in your blood before starting a previous treatment called immunoadsorption.
- You had a good response to immunoadsorption at least 6 months ago, followed by a return of your symptoms.
- Your current Bell Disability Score is between 30 and 60, meaning you can do some light tasks but need rest most of the day.
- You are not taking other immune-modulating medications and have not had certain vaccines or infections recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how a blood-cleaning treatment called immunoadsorption works in patients with ME/CFS (severe fatigue condition) who have specific immune markers. Researchers will track whether this treatment helps reduce symptoms and improve daily functioning.
This trial tests if aripiprazole, a medication often used for other conditions, can help improve neuropsychiatric symptoms like brain fog, mood changes, or fatigue that started after an infection and have lasted at least 3 months.
This trial tests if filtering certain antibodies from the blood can help people with long COVID who experience post-exertional malaise (PEM) and reduced function. It aims to see if this treatment reduces symptoms and improves daily life.
This study looks at how chronic infections and inflammation affect people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) compared to healthy people. Researchers want to understand what causes symptoms and find better ways to help.
This trial tests a new treatment for ME/CFS (chronic fatigue syndrome) that includes symptoms like dizziness when standing. It uses a smartphone app to track your progress and aims to see if the treatment can improve your daily life.
This trial tests if rituximab, a drug that affects the immune system, can help people with ME/CFS. You'll receive the drug in the hospital and be monitored for safety and improvement.
Hear when a new Post-acute Infectious Syndrome (PAIS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.